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Summary
Objective: In order to improve the monitoring of disease progression and therapeutic effec-
tiveness in the management of HIV/AIDS in a resource-limited setting, this study was carried out
to establish a correlation between total lymphocyte counts (TLC) and CD4 lymphocyte counts in
HIV-1 infected/AIDS adults in Yaounde´, Cameroon.
Methods: Full blood counts, differential white, and CD4 counts were measured in 149 patients
using standard methods. The correlation coefficient established correlation between values.
Sensitivity, specificity, and positive predictive values were calculated as required.
Results: The mean TLC, CD4 count, and CD4% as well as CD4/CD8 ratios were
1.932  0.895  109/L, 268  183 cells/mm3, 14.51  15.9%, and 0.34  0.25, respectively. Only
a weak correlation was observed between TLC and CD4 counts (r = 0.41, p = 0.05). As a predictor
of CD4 count, TLC cut-offs <2.0 and <1.0  109/L were unable to predict these values reliably,
but showed that at TLC cut-offs of <1.0  109/L there was a high chance of CD4 counts being
under 200 cells/mm3.
Conclusions: These data suggest that TLC are of limited value in predicting CD4 counts and should
not be substituted for CD4 counts whenever possible. However, TLC may be reliably used in
designing algorithms and programs for initiating patientmanagement and follow-up in this setting.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.§ Presented as ‘‘Correlation between total lymphocyte counts and
CD4 counts in HIV-1 positive adults in Yaounde´’’, XIV International
AIDS Conference, Barcelona, Spain, July 7—12, 2002; Abstract No.
MoPeB3099.
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The prevalence of HIV/AIDS in Sub-Saharan Africa has
reached alarming levels, with about 66% of the 39.4 million
people infected living in countries of this region.1 These are
the countries with the least available resources to cope with
the magnitude of the pandemic. Thus, the socio-economic
impact has been overwhelming.Published by Elsevier Ltd. All rights reserved.
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pandemic, appropriate management of those already
infected is essential to reduce morbidity and mortality.
Currently, management requires that disease stage, treat-
ment, and progression be monitored with the use of sophis-
ticated laboratory tests such as the measurements of plasma
viral load (VL) and CD4 counts.2—4 These tests require sophis-
ticated and expensive equipment usually not readily avail-
able or accessible inmost countries of Sub-Saharan Africa and
other resource-limited settings.5
In Cameroon, there are currently six laboratories in which
CD4 counts can be reliably performed at a cost of US$25—40,
and two for viral load measurements at a cost of US$75—78.
Cameroon is a country with a GNP per capita in the range of
US$600—650. Thus, these tests are very expensive for an
average Cameroonian. On the other hand, other routine tests
also useful in monitoring therapy include the full blood count
with a differential white cell count. This is more easily
accessible through varying techniques, even in rural health
institutions of the country. Thus, if a clear correlation was
established between total lymphocyte counts (TLC) and CD4
counts, this could be an invaluable tool for monitoring
patients in Cameroon and other resource-limited countries.
Hence, this study was undertaken to describe the correla-
tion between TLC and CD4 counts in HIV/AIDS patients in
Yaounde´ at various stages of their disease, and to determine
whether TLC could be used to predict CD4 counts in this
population.
Methodology
This was a cross-sectional study in which clinical and demo-
graphic data were obtained from an interview and physical
examination of each patient after informed consent. Blood
samples were collected during that visit from each partici-
pant, corresponding respectively to different stages of their
disease evolution (HIV diagnosis and/or initiation/monitoring
of anti-retroviral treatment (very few)). For each patient
5 mL of whole blood was drawn from a peripheral vein into
tri-potassium EDTA tubes between 8 and 10 a.m. in the
morning. All samples were analyzed within 4 h of collection
for full blood counts, differential white cell counts, and
lymphocyte subset measurements.Table 1 Mean total lymphocyte counts (TLC) and CD4 counts and
cut-off values
Parameter Mean  1SD
TLC (109/L) 1.932  0.895
CD4 (cells/mm3) 268  183
CD4% 14.51  15.9
CD4/CD8 ratio 0.34  0.25
Correlation with TLC cut off points:
CD4 <100 (cells/mm3)
TLC <1.0  109/L
TLC <2.0  109/L
CD4 <200 (cells/mm3)
TLC <1.0  109/L
TLC <2.0  109/LFull blood counts were measured using an automatic
electronic particle counter (SYSMEX F820 micro cell counter,
Kobe, Japan) and the differential white cell counts were
estimated by microscopy on a May—Grunwald—Giemsa-
stained thin blood film. T-cell subset analyses for CD4 counts
were done by conventional flow cytometry using a Becton—
Dickinson FACScount (California, USA). The revised 1993
Centers for Disease Control (CDC) classification of AIDS
patients6 was used to categorize the patients into categories
A, B, and C.
All data were analyzed using Epi-InfoTM software, version
6.0. The correlation coefficient was used to establish corre-
lation between TLC and CD4 counts. Values of r of<0.59 were
considered a weak correlation, 0.60—0.69, a moderate cor-
relation, and equal or >0.70 a strong correlation. The sensi-
tivity, specificity, and positive and negative predictive values
were calculated at various TLC cut-offs. The analysis of
variance was used to determine the level of statistical sig-
nificance between continuous variables and categorical vari-
ables. Values of p less than or equal to 0.05 were considered
statistically significant.
Results
Of 149 patients studied, 87 (58.4%) were females and 62
(41.6%) males. The females were on average younger than
the males, with mean ages of 33.9  6.7 and 37.3  8.2
years, respectively. About 84.5% of cases were symptomatic
with 54.3% in category C of the CDC classification. Only 5.4%
of the patients seen were on antiretroviral drugs.
The mean  standard deviation (SD) of TLC and
CD4 counts/CD4% were respectively 1.932  0.895  109/L
and 268  183 cells/mm3/14.51  15.9%, while the mean 
SD of CD8 counts and CD4/CD8 ratio were 874  459 cells/
mm3 and 0.34  0.25, respectively (Table 1).
An overall weak correlation was observed between TLC
and CD4 counts for thewhole group (Table 1). This correlation
was generally further weakened when samples were strati-
fied into groups according to age, sex, and clinical category. A
moderate correlation was, however, observed between TLC
<2.0  109/L and CD4 <100 cells/mm3 (r = 0.60; Table 1).
The correlations between TLC, and CD4% and the CD4/CD8
ratio were generally found to be weak.correlation between mean TLC and CD4 counts at various TLC
Correlation with TLC (r value) p value
0.41 0.05
0.16 0.10
0.03 0.10
0.41 0.10
0.60 0.10
0.31 0.10
0.31 0.10
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Table 2 Prediction of CD4 counts by TLC cut-off values
Sensitivity (%) Specificity (%) PPV (%)
CD4 <100 (cells/mm3)
TLC cut-off <1.0  109/L 34.6 95.1 60.0
TLC cut-off <2.0  109/L 84.6 42.3 23.7
CD4 <200 (cells/mm3)
TLC cut-off <1.0  109/L 20.3 96.7 80.0
TLC cut-off <2.0  109/L 76.3 46.7 48.4
PPV: Positive predictive value.As a predictor of CD4 count, TLC <2.0  109/L had a high
sensitivity (84.6%) to detect CD4 counts less than 100 cells/
mm3 but a low specificity (42.3%) and positive predictive
value (23.7%). When the TLC cut-off was lowered to
<1.0  109/L, the specificity and positive predictive values
were respectively 95.1% and 60% while the sensitivity
reduced considerably to 34.6% (Table 2).
On the other hand, to predict CD4 counts<200 cells/mm3,
TLC <2.0  109/L had a high sensitivity (76.3%), a specificity
of 46.7%, and a positive predictive value of 48.4%. When the
TLC cut-off was lowered to <1.0  109/L, the specificity and
positive predictive values increased to 96.7% and 80% respec-
tively, and the sensitivity was 20.3% (Table 2).
Discussion
Although several studies have been carried out in different
contexts in an attempt to recommend TLC use over CD4
counts, the results have varied widely. It is essential for each
race and community to establish its own correlation because
of possible racial and environmental influences.7,8 Such
environmental factors may include endemic disorders that
are known to impact leukocyte counts. For example, malaria
is an endemic infection in some countries including Camer-
oon, and has been shown to cause neutropenia.9
Of 149 cases analyzed, 84.5% were symptomatic with
54.3% in category C of the revised 1993 CDC classification.
The cost of healthcare as well as the low socio-economic
level of the country could explain why people seek medical
care only in advanced stages. Based on the CDC definition for
AIDS,6 antiretrovirals (ARV) are proposed for patients in
categories A3, B3, and C1, C2 and C3. Thus, all patients with
CD4 counts <200 cells/mm3 are recommended to start ARV.
Yet only 5.4% of our patients were already on ARV drugs. Many
patients may not have qualified for treatment based on this
classification because this classification requires prior knowl-
edge of CD4 counts. Furthermore, the lack of financial access
to the drugs may be a contributing factor even when they are
appropriately prescribed.
The mean  SD of TLC, CD4 and CD8 counts, CD4%, and
CD4/CD8 ratio were respectively 1.932  0.895  109/L,
268  183 cells/mm3, 874  459 cells/mm3, 14.51  15.9,
and 0.34  0.25. These mean values, although higher in
males than females, were not statistically different
( p > 0.05). These findings, however, contradict those
reported by Reichert et al.,10 Tugume et al.,11 Zekeng
et al.,12 and Mbanya et al.,13 who reported higher values
for females than for males. This inconsistency may be due toour relatively smaller sample size compared to those of the
other studies. In fact, Reichert et al.10 had earlier reported
the possibility that small sample sizes could be the reason for
contradictory findings on gender variations in lymphocyte
subset values.
An overall weak correlation was observed between TLC
and CD4 counts for the whole group (r = 0.41, p = 0.05), with
a moderate correlation observed between TLC <2.0  109/L
and CD4 <100 cells/mm3 (r = 0.60, p = 0.10). Other authors
have reported similar findings. Guarner et al.14 found a poor
correlation of TLC and CD4 counts (r = 0.59). Van der Ryst
et al.15 found a moderate correlation between these values,
but which was considerably weakened when the CD4 counts
were grouped into three classes. When CD4 counts
<100 cells/mm3 or <200 cells/mm3 and TLC <1.0  109/L
or <2.0  109/L were matched, a moderate correlation
(r = 0.60, p = 0.10) was observed only between CD4
<100 cells/mm3 and TLC <2.0  109/L. With a TLC cut-off
of <1.0  109/L, there is a 96.7% chance that CD4 counts are
less than 200 cells/mm3, suggesting that it may be cost
effective not to measure CD4 counts when TLC is
<1.0  109/L. Incidentally, the World Health Organization
(WHO)16 recommended that where CD4 counts cannot be
available, that TLC of <1.2  109/L be considered suffi-
ciently low to initiate ARV therapy. Our findings suggest that
the TLC is a poor predictor of CD4 counts, comparable to
those of Van der Ryst et al.,15 in which they demonstrated
that a TLC less than or equal to 2.0  109/L had a sensitivity
of 90.3% to detect patients with a CD4 count of <200 cells/
mm3, but a specificity of only 53.7%, confirming that TLC is
not a good predictor of CD4 counts. Interestingly, other
studies have observed a good correlation between TLC and
CD4 counts. Beck et al.3 reported this correlation in patients
in London, UK to be more marked among the symptomatic
cases. In another study in Uganda, Kamya et al.17 reported a
good correlation between TLC and CD4 counts. However, they
also noted that the TLC cut-off of 1.2  109/L recommended
by the WHO did not serve to identify WHO stage 2 and 3
patients with CD4 counts <200 cells/mm3.
At late stages of HIV infection there is severe depletion of
CD4 cells. Sincemost of our patients were already in category
C, this explains the very low CD4 counts and possibly the poor
correlation of CD4 counts to TLC. Furthermore, since we
measured TLC by multiplying the percentage of lymphocytes
(from the differential count) by the white blood cell count
(WBC), any variations in the other components of the WBC
would indirectly influence the percentage of lymphocytes
and hence the TLC. The high prevalence of opportunistic
infections at late stages of HIV infection would certainly lead
160 D. Mbanya et al.to alterations in the relative percentages of the different
components of the differential white cell count. These vir-
tual modifications of the TLC could also be another reason for
the poor correlation found between TLC and CD4 counts.
In the advent of HIV/AIDS there has been an upsurge in
tuberculosis and other infections that may impact TLC,18 and
hence misdirect the decision to start or modify ARV treat-
ment in some patients. Other sexually transmitted infections
such as syphilis are also closely associated with HIV/AIDS and
maymodify TLC.19,20 Thus, it is essential that each patient be
reliably monitoredwith TLC only based on studies established
within their given population.
There are more and more initiatives being created and
implemented worldwide in order to increase access to ARV
therapy for HIV/AIDS patients in resource-limited settings.
These include the WHO ‘3 by 5’, the PEPFAR, Melinda and Bill
Gates, Hope for the African Child Initiative, and others. This
means that more patients will soon be able to start ARV.
However, the pre-treatment laboratory requirements as well
as adequate monitoring of efficacy, tolerance, and toxicity
during treatment are indispensable in this process. Thus,
although our findings suggest that TLCs are of limited value in
predicting CD4 counts and should not be substituted for CD4
counts in patient management and follow-up in this popula-
tion, nevertheless, TLC can be used in resource-restrained
settings; a very low TLC could be used to develop appropriate
algorithms for managing these cases and could serve as a
useful guide for initiating chemoprophylaxis for opportunistic
infections in severely immune-suppressed individuals (CD4
<200 cells/mm3).
Hence we recommend that while TLC values may be
useful, that less sophisticated and less costly methods of
determining CD4 counts such as microvolume fluorimetry21
and ELISA techniques be evaluated and made available for
use in resource-limited settings.
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